Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022.

Authors :: Chow EPF
Stevens K
De Petra V
Chen MY
Bradshaw CS
Sherry NL
Barbee LA
Vodstrcil LA
Aguirre I
Seib KL
Maddaford K
Williamson DA
Howden BP
Fairley CK
Source :: The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. e1121-e1125.
Publication Year :: 2024
Abstract: While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia.<br />Competing Interests: Potential conflicts of interest. All authors: No reported conflicts.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Full Text Access

Tools